Quarterly infographic: MRSA, MSSA and Gram-negative bacteraemia and CDI, data up to April to June 2025
Updated 9 October 2025
Applies to England
Gram-negative bacteraemias (E. coli, Klebsiella spp. and P. aeruginosa)
Pseudomonas aeruginosa (P. aeruginosa) bacteraemia
April to June 2024: 7.6 out of every 100,000 persons developed a P. aeruginosa bacteraemia.
April to June 2025: 7.4 out of every 100,000 persons developed a P. aeruginosa bacteraemia.
Klebsiella species (spp.) bacteraemia
April to June 2024: 22.2 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
April to June 2025: 22.5 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
Escherichia coli (E. coli) bacteraemia
April to June 2024: 76.6 out of every 100,000 persons developed an E. coli bacteraemia.
April to June 2025: 78.3 out of every 100,000 persons developed an E. coli bacteraemia.
Staphylococcus aureus (S. aureus) MRSA and MSSA bacteraemia and Clostridioides difficile (C. difficile) infections
Meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia
April to June 2024: 1.8 out of every 100,000 persons developed an MRSA bacteraemia.
April to June 2025: 1.9 out of every 100,000 persons developed an MRSA bacteraemia.
Meticillin-susceptible Staphylococcus aureus (MSSA) bacteraemia
April to June 2024: 23.2 out of every 100,000 persons developed an MSSA bacteraemia.
April to June 2025: 24.2 out of every 100,000 persons developed an MSSA bacteraemia.
Clostridioides difficile (C. difficile) infection
April to June 2024: 33.1 out of every 100,000 persons developed a C. difficile infection.
April to June 2025: 29.8 out of every 100,000 persons developed a C. difficile infection.